Atopic dermatitis is a chronic inflammatory intensively pruritic skin disease. Patients with moderate-to-severe atopic dermatitis or with difficult-to-treat areas are candidates for systemic therapy, especially when topical therapy is inadequate. Currently, we have available not only conventional immunosuppressive systemic therapy, but also targeted biological therapy, which has shown a remarkable reduction in clinical severity with a good safety profile. Dupilumab has been approved to treat moderate-to-severe atopic dermatitis. Even though the therapy has been available for more than 3 years, there are still limited data regarding the treatment of patients with concomitant cancer. Previous immunosuppressive treatment for atopic dermatitis, such as cyclosporine or azathioprine, poses a safety risk for patients with malignant disease. We present a case series of three patients with advanced cancer and severe atopic dermatitis treated with dupilumab for an average of 17 months with a great response toward atopic dermatitis without cancer recurrence. One patient had colorectal cancer' the second and the third both had cancer duplicity-colorectal and kidney cancer and penile squamous cell carcinoma with prostate cancer. Our cases suggest that dupilumab can safely control atopic dermatitis in patients with advanced cancer.

Department of Dermatovenereology 3rd Faculty of Medicine Charles University and Kralovske Vinohrady University Hospital 10034 Prague Czech Republic

Zobrazit více v PubMed

Barbarot S., Auziere S., Gadkari A., Girolomoni G., Puig L., Simpson E.L., Margolis D.J., De Bruin-Weller M., Eckert L. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73:1284–1293. doi: 10.1111/all.13401. PubMed DOI

Bieber T. Atopic dermatitis. Ann. Dermatol. 2010;22:125. doi: 10.5021/ad.2010.22.2.125. PubMed DOI PMC

Zheng T., Jinho Y., Oh M.H., Zhu Z. The atopic march: Progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol. Res. 2011;3:67–73. doi: 10.4168/aair.2011.3.2.67. PubMed DOI PMC

Silverberg N.B., Silverberg J.I. Inside out or outside in: Does atopic dermatitis disrupt barrier function or does disruption of barrier function trigger atopic dermatitis? Cutis. 2015;96:359–361. PubMed

Martin S., Brown T., Fehnel S., Deal L.S., Katz E.G., Chiou C.-F. The atopic dermatitis itch scale: Development of a new measure to assess pruritus in patients with atopic dermatitis. J. Dermatolog. Treat. 2020;31:484–490. doi: 10.1080/09546634.2020.1713971. PubMed DOI

Paller A., Jaworski J.C., Simpson E.L., Boguniewicz M., Russell J.J., Block J.K., Tofte S., Dunn J.D., Feldman S.R., Clark A.R., et al. Major comorbidities of atopic dermatitis: Beyond allergic disorders. Am. J. Clin. Dermatol. 2018;19:821–838. doi: 10.1007/s40257-018-0383-4. PubMed DOI

Li J.C., Fishbein A., Singam V., Patel K.R.B., Zee P.C., Attarian H., Cella D., Silverberg J.I.M. Sleep disturbance and sleep-related impairment in adults with atopic dermatitis: A cross-sectional study. Dermatitis. 2018;29:270–277. doi: 10.1097/DER.0000000000000401. PubMed DOI PMC

Whiteley J., Emir B., Seitzman R., Makinson G. The burden of atopic dermatitis in US adults: Results from the 2013 National Health and Wellness Survey. Curr. Med. Res. Opin. 2016;32:1645–1651. doi: 10.1080/03007995.2016.1195733. PubMed DOI

Wan J., Shin D.B., Syed M.N. 31772 malignancy risk among children and adults with atopic dermatitis in a population-based cohort. J. Am. Acad. Dermatol. 2022;87:AB79. doi: 10.1016/j.jaad.2022.06.350. DOI

Bickers D.R., Lim H.W., Margolis D., Weinstock M.A., Goodman C., Faulkner E., Gould C., Gemmen E., Dall T. The burden of skin diseases: 2004: A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J. Am. Acad. Dermatol. 2006;55:490–500. doi: 10.1016/j.jaad.2006.05.048. PubMed DOI

Torres T., Ferreira E.O., Goncalo M., Mendes-Bastos P., Selores M., Filipe P. Update on atopic dermatitis. Acta Med. Port. 2019;32:606–613. doi: 10.20344/amp.11963. PubMed DOI

Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A., Gieler U., Girolomoni G., Lau S., Muraro A., et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part, I.I. J. Eur. Acad. Dermatol. Venereol. 2018;32:850–878. doi: 10.1111/jdv.14888. PubMed DOI

Simpson E.L., Bieber T., Guttman-Yassky E., Beck L.A., Blauvelt A., Cork M.J., Silverberg J.I., Deleuran M., Kataoka Y., Lacour J.-P., et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N. Engl. J. Med. 2016;375:2335–2348. doi: 10.1056/NEJMoa1610020. PubMed DOI

Chovatiya R., Paller A.S. JAK inhibitors in the treatment of atopic dermatitis. J. Allergy Clin. Immunol. 2021;148:927–940. doi: 10.1016/j.jaci.2021.08.009. PubMed DOI PMC

Simon B., Bieber T. Systemic therapy for atopic dermatitis. Allergy. 2014;69:46–55. doi: 10.1111/all.12339. PubMed DOI

Blauvelt A., de Bruin-Weller M., Gooderham M., Cather J.C., Weisman J., Pariser D., Simpson E.L., Papp K.A., Hong H.C.-H., Rubel D., et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287–2303. doi: 10.1016/S0140-6736(17)31191-1. PubMed DOI

Halling A.-S., Loft N., Silverberg J.I., Guttman-Yassky E., Thyssen J.P. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. J. Am. Acad. Dermatol. 2021;84:139–147. doi: 10.1016/j.jaad.2020.08.051. PubMed DOI

Seegräber M., Srour J., Walter A., Knop M., Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev. Clin. Pharmacol. 2018;11:467–474. doi: 10.1080/17512433.2018.1449642. PubMed DOI

FDA/CEDR Resources Page. Food and Drug Administration Web Site. [(accessed on 13 January 2023)]; Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s044lbl.pdf.

Braddock M., Hanania N.A., Sharafkhaneh A., Colice G., Carlsson M. Potential risks related to modulating interleukin-13 and interleukin-4 signalling: A systematic review. Drug Saf. 2018;41:489–509. doi: 10.1007/s40264-017-0636-9. PubMed DOI PMC

Fowler E., Rosen J., Lev-Tov H., Yosipovitch G. Two Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis. Acta Derm. Venereol. 2019;99:899–900. doi: 10.2340/00015555-3201. PubMed DOI

Qiu Y., Ali K., Lou H., Shan J., Wu L. Successful Treatment of Atopic Dermatitis with Dupilumab in a Patient with Non-Hodgkin’s Lymphoma. Acta Derm.-Venereol. 2022;102:adv00625. doi: 10.2340/actadv.v101.224. PubMed DOI PMC

Kojanová M., Tánczosová M., Štrosová D., Cetkovska P., Fialova J., Dolezal T., Machovcova A., Gkalpakiotis S., on behalf of the BIOREP Study Group Dupilumab for the treatment of atopic dermatitis: Realworld data from the Czech Republic BIOREP registry. J. Dermatol. Treat. 2022;33:2578–2586. doi: 10.1080/09546634.2022.2043545. PubMed DOI

Nettis E., Ferrucci S.M., Ortoncelli M., Pellacani G., Foti C., Di Leo E., Patruno C., Rongioletti F., Argenziano G., Macchia L., et al. Use of dupilumab in 543 adult patients with moderate-to-severe atopic dermatitis: A multicenter, retrospective study. J. Investig. Allergol. Clin. Immunol. 2022;32:124–132. doi: 10.18176/jiaci.0641. PubMed DOI

Siliquini N., Viola R., Giura M.T., Fierro M.T., Ribero S., Ortoncelli M. Case of bladder cancer during Dupilumab therapy: Just an incidental event? Dermatol. Ther. 2020;33:e13854. doi: 10.1111/dth.13854. PubMed DOI

Owji S., Dubin D.P., Yassky D., Han J., Tan K., Jagannath S., Parekh S., Gulati N. Dupilumab in Multiple Myeloma: A Case Series. Clin. Lymphoma Myeloma Leuk. 2022;22:928–932. doi: 10.1016/j.clml.2022.09.002. PubMed DOI

Neoadjuvant Dupilumab in Men with Localized High-Risk Prostate Cancer—Full Text View (No Date) Full Text View—ClinicalTrials.gov. [(accessed on 13 January 2023)]; Available online: https://clinicaltrials.gov/ct2/show/NCT03886493.

Fitzgerald B.G., Marron T.U., Hall N., O’Grady D., LaMarche N., Hennequin C., Hegde S., Maier B., Le Berichel J., Chadda U., et al. A phase 1b/2 trial of dupilumab given in conjunction with pd-(l)1 blockade in the treatment of relapsed/refractory metastatic NSCLC. J. Clin. Oncol. 2022;40:TPS9139. doi: 10.1200/JCO.2022.40.16_suppl.TPS9139. DOI

Wollenberg A., Thomsen S.F., Lacour J.P., Jaumont X., Lazarewicz S. Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence. World Allergy Organ. J. 2021;14:100519. doi: 10.1016/j.waojou.2021.100519. PubMed DOI PMC

Helby J., Bojesen S., Nielsen S., Nordestgaard B. IGE and risk of cancer in 37 747 individuals from the general population. Ann. Oncol. 2015;26:1784–1790. doi: 10.1093/annonc/mdv231. PubMed DOI

Eshtiaghi P., Gooderham M.J. Dupilumab: An evidence-based review of its potential in the treatment of atopic dermatitis. Core Evid. 2018;13:13–20. doi: 10.2147/CE.S133661. PubMed DOI PMC

Fargnoli M.C., Esposito M., Ferrucci S., Girolomoni G., Offidani A., Patrizi A., Peris K., Costanzo A., Malara G., Pellacani G., et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J. Dermatol. Treat. 2022;33:1146–1149. doi: 10.1080/09546634.2020.1773379. PubMed DOI